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Idiopathic pulmonary fibrosis is a disease characterized by
progressive, unrelenting lung scarring, with death from respira-
tory failure within 2–4 years unless lung transplantation is per-
formed. New effective therapies are clearly needed. Fibroblast
activation protein (FAP) is a cell surface-associated serine pro-
tease up-regulated in the lungs of patients with idiopathic pul-
monary fibrosis as well as in wound healing and cancer. We
postulate that FAP is not only amarker of disease but influences
the development of pulmonary fibrosis after lung injury. In two
differentmodels of pulmonary fibrosis, intratracheal bleomycin
instillation and thoracic irradiation, we find increasedmortality
and increased lung fibrosis in FAP-deficient mice compared
with wild-type mice. Lung extracellular matrix analysis reveals
accumulation of intermediate-sized collagen fragments in FAP-
deficient mouse lungs, consistent with in vitro studies showing
that FAP mediates ordered proteolytic processing of matrix
metalloproteinase (MMP)-derived collagen cleavage products.
FAP-mediated collagen processing leads to increased collagen
internalization without altering expression of the endocytic
collagen receptor, Endo180. Pharmacologic FAP inhibition
decreases collagen internalization as expected. Conversely, res-
toration of FAP expression in the lungs of FAP-deficient mice
decreases lung hydroxyproline content after intratracheal bleo-
mycin to levels comparable with that of wild-type controls. Our
findings indicate that FAP participates directly, in concert with
MMPs, in collagen catabolism and clearance and is an impor-
tant factor in resolving scar after injury and restoring lung
homeostasis. Our study identifies FAP as a novel endogenous
regulator of fibrosis and is the first to show FAP’s protective
effects in the lung.
Idiopathic pulmonary fibrosis, the most common of the idi-
opathic interstitial pneumonias, is characterized by inexorable
progressive lung injury and scarring, with eventual deathwithin
2–4 years from the time of diagnosis in the absence of lung
transplantation (1). The etiology of the disease is poorly under-
stood, and current Food and Drug Administration-approved
treatments have only limited impact on the course of the dis-
ease (2–4).
Fibroblast activation protein (FAP,2 also known as seprase) is
a 95-kDa cell surface, type II integral serine protease belonging
to the post-proline dipeptidyl aminopeptidase (DPP) family (5)
that is specifically induced on lung fibroblasts in patients with
idiopathic pulmonary fibrosis, in particular at the leading edge
of fibrosis (6). The DPP family of serine proteases cleaves
amino-terminal dipeptides from polypeptides with L-proline or
L-alanine at the penultimate position. FAP is unique in that it
displays additional in vitro endopeptidase (7), gelatinase, and
potentially collagenase activity (8, 9). FAP expression is
restricted, occurring at high levels onmesenchymal cells during
embryogenesis (10) and then is repressed shortly after birth. In
conditions associated with matrix remodeling, such as wound
healing (11), fibrosis (6, 12, 13), and cancer (5, 14–17), however,
FAP expression is up-regulated on activated fibroblasts. FAP
has also been detected on pericytes, bonemarrow-derivedmes-
enchymal stem cells (18, 19), and a small population of macro-
phages (20, 21).
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FAP’s in vivo substrates remain unclear. Despite a lack of
direct evidence, FAP is assumed to degrade ECM components,
including type I collagen in vivo (9, 22, 23). In support of this
idea, we have observed that FAP deficiency leads to increased
tumor collagen content in a syngeneic transplant model of
colon cancer and an endogenous K-ras-driven murine lung
tumormodel (24). In general, FAP expression by tumor stromal
cells correlates with greater tumor aggressiveness, whereas
inhibition of FAP activity curtails tumor growth and invasive-
ness (16, 24–27). Not surprisingly, cancer researchers are
actively exploring FAP’s therapeutic potential as a stromal cell
target. In regard to fibrosis, however, FAP remains a relatively
understudied protein, and its place in the pathogenesis of this
disease is unknown.
The studies described hereinwere designed to define the role
of FAP in the development of pulmonary fibrosis in vivo,
employing a genetic approach with global knock-in mice in
which the Fap gene has been replaced by a lacZ gene that is
expressed under the control of the endogenous Fap promoter
(28). Two well established complementary murine models of
pulmonary fibrosis, intratracheal bleomycin and thoracic irra-
diation (29), were used. FAP-deficient mice demonstrated
increased mortality and increased lung collagen content com-
pared with wild-type mice in both models. This phenotype was
not attributable to increased myofibroblast induction, height-
ened collagen synthesis, or appreciable differences in MMP
activity. Instead, we present evidence that loss of FAP expres-
sion directly results in defective processing of type 1 collagen
and impaired ECM remodeling. In addition, although we did
not find increased numbers of -smooth muscle actin-positive
cells by immunofluorescence staining, FAP-deficient primary
mouse lung fibroblasts displayed more robust induction of a
myofibroblast phenotype compared with wild-type in response
to TGF-. Our findings are the first to demonstrate that FAP
protects against the development of pulmonary fibrosis after
lung injury.
Experimental Procedures
Animals
Eight- to 12-week-old C57BL/6 male and female mice were
purchased from Charles River Laboratories. FAP-deficient
FAPLacZ/LacZ mice (28) were obtained fromW. J. Rettig and A.
Schnapp (Boehringer Ingelheim Pharma KG, Ingelheim, Ger-
many) and backcrossed 12 generations to a C57BL/6 back-
ground to facilitate fibrosis studies. These FAP-null mice have
been previously characterized and show no developmental nor
overt adult abnormalities under homeostatic conditions
(28). Mice were genotyped as described previously (24). All
mice were housed in a specific pathogen-free animal facility
at theWistar Institute or at the University of Pittsburgh. The
protocols used in this study were approved by the Institu-
tional Animal Care and Use Committee at The Wistar Insti-
tute or the University of Pittsburgh, and all procedures were
conducted according to ethical committee guidelines on ani-
mal welfare and the Guide for the Care and Use of Labora-
tory Animals (30).
TwoMurine Pulmonary Fibrosis Models
Thoracic Irradiation—Micewere anesthetized and irradiated
as described previously (31). In brief, 8–12-week-old female
FAPLacZ/LacZ mice and age/sex-matched controls were anes-
thetized with intraperitoneal xylazine/ketamine. A single frac-
tion of 13.5 Gy was delivered to the thorax of the mice via a
250-kVp orthovoltagemachine. A customized jig provided lead
shielding over the animals’ head/neck and abdomen/pelvis
regions, exposing only the thorax to irradiation. Mice were fol-
lowed for modified survival studies, and survivors were sacri-
ficed 16 weeks after thoracic irradiation for tissue collection.
Intratracheal (i.t.) Bleomycin—8–12-Week-old male
FAPLacZ/LacZ mice and age/sex-matched controls were anes-
thetized with intraperitoneal ketamine/xylazine. A single dose
of bleomycin (1.0–1.75 IU/kg, depending on experiment) was
administered by i.t. injection, using a STEPPERTM repetitive
pipette (TridakTM, LLC) to minimize dose variations due to
pipetting error.Mice were either followed formodified survival
studies or sacrificed at designated time points for tissue collec-
tion.Malemicewere used as they aremore bleomycin-sensitive
than their female counterparts.
Hydroxyproline Assay
Collagen quantification was performed by hydroxyproline
assay as previously described (24). The right lung was consis-
tently dedicated for this assay to allow comparison. Hydroxy-
proline contentmay be converted to collagen content using the
conversion factor of 1g of hydroxyproline corresponds to 6.94
g of collagen.
Immunohistochemistry Staining for FAP and
Immunofluorescence Staining for-SMA
FAP Immunohistochemistry—Antigen retrieval was per-
formed on de-paraffinized lung sections using 10 mM sodium
citrate buffer, pH 6.0, for 20min at 95 °C. Slides were washed at
room temperature and hydrated in PBS. Endogenous peroxi-
dase activity was then quenched with 3% hydrogen peroxide.
Sections were then washed in PBS, 0.05% Tween 20 and endog-
enous avidin and biotin blocked using a commercially available
avidin-biotin blocking kit (Vector Laboratories). Sections were
incubated overnight at 4 °C in biotin-conjugated sheep anti-
human FAP antibody (R&D Systems; AF3715; 15 g/ml) or
biotin-conjugated sheep control antibody (R&D Systems;
BAF020;15 g/ml). Sections were then washed in PBS, 0.05%
Tween 20, and specific signal amplification was performed
using an HRP-streptavidin/biotin-XX tyramide-containing
tyramide signal amplification kit (Molecular Probes), followed
by detection using the Vectastain Elite ABC kit (Vector Labo-
ratories). n 3 animals/group.
-SMA Immunofluorescence—Immunofluorescence stain-
ing for -SMA was performed on deparaffinized lung sections
as described previously (24). Prepared slides were incubated
with rabbit anti-SMA (Abcam; ab5694; 1:100; 2g/ml) or iso-
type control antibody at 4 °C overnight. AlexaFluor-568 goat
anti-rabbit IgG (Life Technologies, Inc.; A11036; 1:500) was
used as the secondary antibody. Nuclei were stained with DAPI
(Life Technologies Inc.; 300 nM) and mounted for fluorescence
microscopy. An ImageJ macro was constructed to objectively
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quantify the amount of -SMA signal found in the total area of
lung injury per field. The analysis was performed in a blinded
fashion by an independent observer. For each mouse, all five
lung lobes were examined, with four different 40 images
taken per lobe; n 3–4mice per group. The percentage of total
injured lung area showing positive SMA signal was quantified
by computer assisted morphometry using ImageJ.
Masson Trichrome Staining
Lung sections were deparaffinized and rehydrated as
described previously (24). Sections were then incubated in pre-
heated Bouin’s solution (Rowley Biochemicals) at 56 °C for 1 h.
Sections were then cooled and washed in a running tap of H2O
until all yellow color was removed. Nuclei were then stained
with Weigert’s iron hematoxylin (Rowley Biochemicals) for 15
min. Slides were washed in a running tap of H2O for 5 min and
then rinsed with nanopure H2O. Slides were then stained in
Biebrich scarlet-acid fuchsin (Rowley Biochemicals) for 15min,
rinsed with nanopure H2O, and then placed in phosphotung-
stic/phosphomolybdic acid (Rowley Biochemicals) solution for
10 min. This was followed by staining in aniline blue (Rowley
Biochemicals) for 15 min. Slides were then rinsed in nanopure
water, quickly dehydrated in 95 and 100% ETOH, cleared in
xylene, and mounted with coverslips.
Generation of Antibody Specific for Murine FAP
Murine anti-murine FAP antibody 73.3 was produced and
characterized in our laboratory as described (32). The specific-
ity of this antibody was validated based on nonreactivity with
tissues from FAP-null mice compared with analogous positive
control tissues from wild-type mice.
Generation of RecombinantMurine FAP ECD
HEK293 cells transfectedwithmurine FAPECDcontaining a
5-His and 3-FLAG tag were obtained from Dr. Jonathan
Cheng (Fox Chase Cancer Center, Philadelphia) and used to
produce murine FAP ECD that was purified as described pre-
viously (32).
Immunoblotting andMurine FAP Immunoprecipitation
Immunoblotting of mouse lung homogenates and/or cell
lysates was performed as described previously (24). Antibodies
used were as follows: TIMP1 antibody (R&D Systems; AF980;
0.1g/ml); p-Smad2 (Ser-245/-250/-255) (Cell Signaling Tech-
nology; catalog no. 3104; 1:500); Smad2/3 (Cell Signaling Tech-
nology; catalog no. 5678; 1:500); -SMA (Abcam; AB5694;
1:5000); type I collagen (EMDMillipore; AB765P; 1:500); sheep
anti-human FAP (R&D Systems; AF3715; 0.5 g/ml); -actin
(Cell Signaling Technology; catalog no. 4967; 1:1000); and
GAPDH (Sigma; catalog no. G9545; 1:5000). Immunoblotting
for the collagen receptor, uPARAP/Endo180, was performed
on non-reduced lysates of primarymouse lung fibroblasts using
a mouse monoclonal anti-Endo180 antibody generously pro-
vided by Daniel H. Madsen (33), 2 g/ml working concentra-
tion.HRP-conjugated rabbit anti-goat, goat anti-rabbit, donkey
anti-sheep, and goat anti-mouse secondary antibodies were
obtained from Jackson ImmunoResearch.
Murine FAP IP/IB—Immunoblotting for detection ofmurine
FAP was performed after immunoprecipitation. Immunopre-
cipitation was performed from equal amounts of protein (1 mg
of lung homogenate/sample). Sampleswere precleared by incu-
bating with 50g of isotype IgG1-conjugated agarose beads for
2 h and nutating at 4 °C. The samples were then spun down at
2000 rpm at 4 °C, and the supernatant was incubated with
either 50 g of anti-FAP 73.3-conjugated protein A-agarose
beads or 50 g of isotype IgG1-conjugated protein A-agarose
beads overnight at 4 °C. The samples were then spun down at
4 °C at 2000 rpm; the supernatant was aspirated off, and the
remaining beads were washed three times with 25 mM HEPES,
pH 7.5, containing 0.1% Triton X-100, 300 mM NaCl, 0.5 mM
DTT, 0.2 mM EDTA, 1.5 mM MgCl2, containing 20 mM -glyc-
erophosphate, 1mMNa3VO4, 10mMNaF, 10mM sodium pyro-
phosphate, and protease inhibitor mixture (Roche Applied Sci-
ence) at 25mg/ml, followed by a final PBSwash. The beadswere
resuspended in 2 Laemmli buffer DTT and boiled, and 20
l of each sample was resolved on an 8% SDS-polyacrylamide
gel. The remainder of the protocol is as above, for immunoblot-
ting, with the membranes incubated with primary anti-murine
FAP 73.3 antibody overnight, followed by secondary HRP-goat
anti-mouse antibody (Jackson ImmunoResearch).
Human FAP IP/IB—Immunoblotting for hFAP expression in
our adenovirus experiments was performed after immunopre-
cipitation. Mouse lung samples were homogenized in immu-
noprecipitation lysis/wash buffer (Pierce) with complete
mini-protease inhibitors (Roche Applied Science), and immu-
noprecipitation was performed with a commercial co-immu-
noprecipitation kit (Pierce) according to the manufacturer’s
instructions. Briefly, 20 g of mouse anti-hFAP antibody (F19,
Ludwig Institute for Cancer Research) and species-matched
mouse IgG isotype control (MAB002, R&D Systems) were cou-
pled and immobilized to AminoLink Plus coupling resin
included in the kit. 1 mg of the mouse lung lysates were pre-
cleared with agarose-resin from the kit and then incubated (16
h; 4 °C) with antibody-bound or isotype IgG control-bound
AminoLink resin. The boundprotein-antibody complexeswere
washed with immunoprecipitation lysis/wash buffer and then
eluted with the elution buffer. Samples were heated (95 °C; 5
min) and separated by two-dimensional electrophoresis on
4–12% NuPAGE BisTris gels (Invitrogen Life Technologies,
Inc.) followed by immunoblotting with sheep anti-human FAP
antibody (R&D Systems; AF3715; 0.5 g/ml) followed by HRP-
conjugated donkey anti-sheep secondary antibody (Jackson
ImmunoResearch, 1:5000). All immunoblots were quantified
using ImageJ.
Quantitative RT-PCR
Mouse lungs were homogenized in TRIzol (Invitrogen) and
processed for RNA extraction following the manufacturer’s
protocol. After quantification and assessment of quality/degra-
dation by electrophoresis, reverse transcription was performed
using the standard protocol for the TaqMan reverse transcrip-
tion kit (Applied Biosystems). Gene expression levels were then
assayed by real time PCR on an ABI Prism 7900HT real time
PCR system (Applied Biosystems) using SYBR Green reagents
and procedures. The results are expressed as relative gene
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expression levels normalized to -actin (gene/-actin). Murine
primer sequences are as follows: FAP-F, 5-CACCTGATCGG-
CAATTTGTG; FAP-R, 5-CCCATTCTGAAGGTCGTAGA-
TGT; -actin-F, 5-TCAGCAAGCAGGAGTACGATG; -
actin-R, 5-AACAGTCCGCCTAGAAGCACTT; SMA-F, 5-
CCAGAGCAAGAGAGGGATCCT; SMA-R, 5-TGTCGTC-
CCAGTTGGTGATG; Col11-F, 5-GCACGAGTCACACC-
GGAACT; Col11-R, 5-AAGGGAGCCACATCGATGAT;
Col12-F, 5-CTACTGGTGAAACCTGCATCCA; Col12-R,
5-GGGCGCGGCTGTATGAG; Col31-F, 5-TCCTGAAG-
ATGTCGTTGATGTG; Col31-R, 5-TTTTTGCAGTGGT-
ATGTAATGTTCTG; MMP2-F, 5-ACCACCTTAACTGTT-
GCTTTTG; MMP2-R, 5-AGGAAATGCAGTGGAGTG-
GAA; MMP3F, 5-GGAGCTAGCAGGTTATCCTAAAAGC;
MMP3-R, 5-TAGAAATGGCAGCATCGATCTTC; MMP7-F,
5-GGTGAGGACGCAGGAGTGAA; MMP7-R, 5-GAAGA-
GTGACTCAGACCCAGA; MMP8-F, 5-AAAAGGGAAGC-
TCAGTCTGTATACTC; MMP8-R, 5-AGAGGGCTGCAGA-
GTTAGTTACCA; MMP9-F, 5-GGACGACGTGGGCTA-
CGT; MMP9-R, 5-CACGGTTGAAGCAAAGAAGGA;
MMP13-F, 5-TTGCCCTGGGAAGGAGAGA; MMP13-R,
5-AGTCCAGCTCAACAAGAAGAAGGT; MMP14(MT1-
MMP)-F, 5-AGTCAGGGTCACCCACAAAGA; MMP14
(MT1-MMP)-R, 5-TTTGGGCTTATCTGGGACAGA; PAI-
1-F, 5-TTGTCCAGCGGGACCTAGAG; PAI-1-R, 5-AAGT-
CCACCTGTTTCACCATAGTCT; CTGF-F, 5-CACTCTG-
CCAGTGGAGTTCA; CTGF-R, 5-AAGATGTCATTGTCC-
CCAGG; TIMP1-F, 5-CCTTCGCATGGACATTATTCTC;
and TIMP1-R,5-TCTCTAGGAGCCCCGATCTG. In our
later adenovirus experiments, we used TaqMan methodology;
mouse lung tissues were homogenized by metal-probe homog-
enizer and total RNA isolated by RNeasy mini kit (Qiagen).
1g of total RNAwas reverse-transcribed into cDNAusing the
high capacity cDNA reverse transcription kit (Applied Biosys-
tems). Quantitative real time PCR was performed using the
TaqMan gene expression assay on an Applied Biosystems
7900HT fast real time PCR system according to themanufactu-
rer’s instructions. TaqMan gene expression master mix
(Applied Biosystems) and commercially designed human FAP
(catalog no. 4331182 ID:Hs00990806_m1) and 18S (catalog no.
4333760F, for detection in mouse, rat, and human) primer/
probe sets were purchased from Applied Biosystems. CT
Ct(FAP)Ct(18S)was used to represent the expression level of
human FAP in themouse lung after adenovirus administration.
Gelatin Zymography
Mouse lungs were homogenized in MPER buffer (Pierce) in
the presence of protease inhibitor mixture without EDTA
(Roche Applied Science). Protein concentration was deter-
mined by BCA assay (Pierce), and 20 g of each lung homoge-
nate were mixed with 2 non-reducing sample buffer contain-
ing 2% SDS, 0.1% bromphenol blue, and 40% glycerol. The
samples were incubated at room temperature for 30 min and
then loaded onto 8% SDS-polyacrylamide gels containing 0.5
mg/ml gelatin (Sigma). After electrophoresis, the gels were
washed four times at room temperature for 15 min with 2.5%
Triton X-100 solution and then incubated overnight in activa-
tion buffer containing 50 mM Tris-HCl, 200 mM NaCl, 5 M
ZnCl2, 5 mM CaCl2, and 0.02% NaN3, pH 7.5, for 18 h at 37 °C.
The gels were then stained with 0.125% Coomassie Blue in 60%
methanol and 25% acetic acid for 1 h at room temperature fol-
lowed by destaining in 10% acetic acid with 30%methanol until
bands appeared.
Collagen Zymography
Collagenase activity in lung homogenates was assessed by
collagen zymography as described in the literature (34). In brief,
lungs were homogenized in MPER buffer (Pierce) in the pres-
ence of protease inhibitor mixture without EDTA (Roche
Applied Science). Protein concentration was determined by
BCA assay (Pierce) and 50 g of lung homogenate mixed with
4 non-reducing sample buffer containing 200 mM Tris-HCl,
pH 6.8, 8% SDS, 0.4% bromphenol blue, and 50% glycerol. The
samples were then incubated at room temperature for 10 min
and loaded onto 8% SDS-polyacrylamide gels containing 0.5
mg/ml rat tail type 1 collagen (BD Biosciences). After electro-
phoresis, the gels were washed twice for 1 h at room tempera-
ture with 2.5% Triton X-100 solution and then incubated in
activation buffer containing 100 mM Tris, 5 mM CaCl2, 150 mM
NaCl, 0.01% Brij-35 at pH 8.0 for 40 h at 37 °C. The gels were
then stained with 0.25% Brilliant Blue R-250 in 40% methanol
and 10% acetic acid solution for 2 h at room temperature. The
gels were then destained in aqueous 10% methanol and 10%
acetic acid solution until the bands appeared.
Collagen Digests
Gels containing 2 mg/ml rat tail type 1 collagen (BD Biosci-
ences) in PBS were made, using 0.1 M NaOH to neutralize the
collagen pH and incubated at 37 °C for 1 h to promote solidifi-
cation (22). For each 45 g of collagen (i.e. 22.5 l of gel), 0.75
g of recombinant human MMP-1 (R&D Systems) in 12.5 mM
sodium phosphate was added, and the mixture was incubated
for 8 h at 37 °C. GM6001 (50 M) was then added, and the
samplewas incubated for 15min at 37 °C to ensure inhibition of
furtherMMPactivity. Recombinantmurine FAPECDwas then
added in increasing amounts (0.25–5 g) to generate a dose-
response curve. In an additional sample, FAP-ECD (5 g) pre-
incubated for 15 min at 37 °C with PT630 (50 M, Point Ther-
apeutics, Inc.), a pharmacologic inhibitor of both FAP and
dipeptidyl peptidase IV (DPPIV), rather than FAP-ECD alone,
was added to the sample to verify specificity of the assay. After
an 8-h incubation at 37 °C with FAP ECD inhibitor, the col-
lagen digests were prepared for electrophoresis by adding 4
sample buffer and reducing agent and heating at 70 °C for 10
min. Equal volumes of the collagen digests were separated by
two-dimensional electrophoresis on a 4–12% Bis-Tris gel
(Invitrogen) with MES running buffer. A small aliquot of undi-
gested, acid-solubilized type 1 rat tail collagenwas also included
as a reference for intact type I collagen. The soluble fraction of
a collagen gel exposed only to FAP ECD for 8 h at 37 °C (i.e. no
prior digestion with MMP-1) was also included. The gel
was then stained with SimplyBlueTM SafeStain Coomassie
G-250 stain (Invitrogen), destained in nanopure water, and
photographed.
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FAP/TGF- Cleavage Experiments
Recombinantmurine FAP (R&DSystems) was purchased for
these experiments. Enzymatic activity of the protein was con-
firmed by sequential type I collagen digests (i.e.MMP1 followed
by recombinant murine FAP) as outlined above prior to pro-
ceeding with our TGF- experiments. Recombinant proteins
tested as potential candidates for FAP-mediated proteolytic
cleavage were as follows: active recombinant human TGF-
(R&D Systems), recombinant latent human TGF- (LTGF-,
Cell Signaling Technology), and recombinant human latency-
associated peptide (R&D Systems). 1 g of each protein was
incubated either alone, together with 2.5 g of recombinant
murine FAP, or with 2.5 g of FAP preincubated with the
FAP inhibitor, N-(quinoline-4-carbonyl)-Gly-Pro(F,F)-nitrile,
2 mM, at 15 min for 16 h at 37 °C in 25 mM Tris-HCl, 0.25 M
NaCl, pH 8.0, and a total sample volume of 25l. Samples were
then resolved on a 4–12% Bis-Tris gel (Invitrogen) with MES
running buffer, stained for protein using the SilverQuestTM sil-
ver staining kit (ThermoFisher Scientific), per the manufac-
turer’s instructions, and photographed.
Lung ECM Isolation and Detection of Collagen Fragments
Lung ECM was isolated from the lungs of mice 10 days after
i.t. bleomycin versus saline injection using a modification of a
protocol for ECM isolation from murine left ventricles (35–37).
Lungs were washed in wash buffer (nanopure water plus 20mM
EDTA and complete protease inhibitor mixture (Roche
Applied Science)) for 30 min on a rocker at room temperature.
Lungs were then decellularized over a 72–96-h period and
rocking at room temperature, using several changes of decellu-
larization buffer (1% SDS with complete protease inhibitor
mixture and 20 mM EDTA in PBS). Lungs were then washed in
wash buffer for 5 min three times, then overnight, rocking at
room temperature Lungs were then snap-frozen, pulverized,
then homogenized, and sonicated in Protein Extraction Rea-
gent IV (Sigma) with 1 complete protease inhibitor mixture.
Protein concentration was determined by Bradford assay. 0.75
g of each ECM preparation was resolved by two-dimensional
electrophoresis using 3–8% Tris acetate gels (Invitrogen) to
better separate intact collagen forms, and 2.0 g of each ECM
preparation was simultaneously resolved on 4–12% Bis-Tris
gels, to better separate out and detect smaller sized collagen
fragments. Standard protocol for immunoblotting was per-
formed with the exception that the PVDFmembranes were cut
roughly halfway between the 150- and 100-kDa markers to
allow the two halves of the membrane to be incubated in pri-
mary antibody separately. This prevented the primary antibody
from being consumed and bound preferentially to the much
more abundant intact collagen forms in our preparations,
allowing better detection of the intermediate-sized collagen
fragments on the lower portion of the PVDF membrane. Poly-
clonal rabbit anti-mouse type 1 collagen antibody (Millipore)
was used as the primary antibody, followed byHRP-conjugated
goat anti-rabbit secondary antibody (Jackson ImmunoRe-
search). Experiments were repeated in triplicate for a total of
n 3 per group.
PrimaryMouse Lung Fibroblast Culture Experiments
Primarymouse lung fibroblasts were isolated and cultured as
described previously (38). All experiments involving primary
lung fibroblasts were performed three times with cells at P3-P4,
using different animals for isolation of cells for each experi-
ment. Primary mouse lung fibroblasts were plated at a density
of 2  105 cells/well on type 1 collagen-coated 6-well plates.
The exception to this were experiments to detect collagen frag-
ments in cell culture media; here, cells were plated on plastic.
Recombinant human TGF- (R&D Systems) stimulation was
performed at 10 ng/ml. p-Smad2 and Smad 2/3 levelswere eval-
uated after 90 min of recombinant human TGF- exposure.
-SMA protein expression was assessed at 48 h (Fig. 8C) and
72 h (data not shown) of TGF- exposure. Detection of type 1
collagen fragments in cell culture media was performed at 72 h
of TGF- exposure.
Collagen Internalization Experiments
Type I rat tail collagen (BD Biosciences) was labeled with
DyLight 650 (Pierce) as described previously (39). The dye con-
centration was adjusted to achieve 1 dye molecule per 3–5 col-
lagen triple helix labeling efficiency. The unreacted dye was
removed by serial collagen precipitations with 0.9 MNaCl in 0.5
M acetic acid. Purified collagen was solubilized in 2 mM HCl,
characterized by electrophoresis on pre-cast 3–8% Tris acetate
mini-gels (Invitrogen), and collagen concentration was deter-
mined by circular dichroism in a J810 spectrometer (Jasco)
using known dilutions of unlabeled type I rat tail collagen (BD
Biosciences) to generate a standard curve. Gels containing 400
g/ml DL650-labeled collagen weremade in 12-well tissue cul-
ture plates and allowed to dry overnight. The following day, the
gels were washed with sterile water to remove excess salts and
equilibrated with 1 PBS followed by DMEM washes. Mouse
lung fibroblasts from wild-type or FAPLacZ/LacZ mice were pre-
treated with 20 M E-64d (Sigma), a lysosomal inhibitor that
prevents lysosomal degradation of internalized collagen, for
1 h, then seeded at 1.4 105 cells/well on the collagen gels, and
incubated at 37 °C for 9 h in the continued presence of E-64d.
Fibroblasts were similarly plated on unlabeled collagen gels to
serve as appropriate negative controls. Cells were then recov-
ered from the gels, and surface-bound collagenwas removed via
a collagenase IV (Sigma) digestion followed by trypsin to
achieve a single-cell suspension. Cells were then plated on
fibronectin-coated glass coverslips and incubated overnight in
the presence of E-64d. Cells were then fixed with 3.75% para-
formaldehyde and stained with Hoechst dye for nuclei and
AF488-labeled F-actin antibody. Confocal microscopy was
conducted using an Olympus Fluoview 1000 confocal micro-
scope to obtain 15–18 images from five coverslips per group.
Quantitation of the integrated DL650 fluorescence per image
was performed using Metamorph software, and this value was
divided by the nuclei per high power field to calculate DL650
fluorescence/cell for each image. Imaging of fibroblasts seeded
on unlabeled collagen gels confirmed the absence of virtually
any detectable autofluorescence in the DL650 channel in our
controls. Experiments were performed in triplicate. The colla-
gen internalization experiments abovewere also repeated in the
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presence or absence of a selective FAP inhibitor,N-(quinoline-
4-carbonyl)-Gly-Pro(F,F)-nitrile. FAP primary mouse fibro-
blasts derived from wild-type mice were preincubated with
either vehicle control or N-(quinoline-4-carbonyl)-Gly-
Pro(F,F)-nitrile at 1 mM concentration in cell culture media for
1 h. The cells were then seeded onDL650-labeled collagen gels,
and the experiments were carried forward exactly as outlined
previously except that the cells were also maintained in FAP
inhibitor versus vehicle control in addition to the lysosomal
inhibitor, E-64d, for the duration of the experiment. Quantifi-
cation of DL650 fluorescence/cell was performed using NIS
Elements on 15–16 images per condition, using fixed settings
and with the binary threshold set so that there was no signifi-
cant signal seen on negative control images of cells seeded on
unlabeled collagen gels.
Adenoviral Reconstitution of FAP Expression
The full-length human FAP gene sequence was cloned into
the shuttle plasmid, pAdlox, and adenoviruses expressing hFAP
(adeno-hFAP) and empty vector (adeno-Y5) were made and
purified with assistance from the Vector Core Facility at the
University of Pittsburgh. FAP-null and wild-type primary
mouse lung fibroblasts were then transducedwith adeno-hFAP
and adeno-Y5. We confirmed robust FAP expression by both
IPIB and FACS (data not shown). Proceeding to in vivo
experiments, 108 pfu of adeno-hFAP versus adeno-Y5 were
administered by i.t. injection in 40 l of sterile PBS to 8–12-
week-old male FAPLacZ/LacZ mice and age/sex-matched
C57BL/6 controls. 72 h later, 1.0 IU/kg i.t. bleomycin was
administered in 40 l of sterile normal saline to each mouse
(n  6–10/group, four groups total). Mice were later sacri-
ficed at 15 days post-bleomycin for hydroxyproline assay (R
lung) and histological analysis (L lung). Another experiment
was conducted with mice treated with 108 pfu of adeno-
hFAP versus adeno-Y5 alone with animals sacrificed at vari-
ous intervals to examine the changing kinetics of hFAP gene
and protein expression over time.
Statistics
All results are expressed as mean  S.E. Statistical analysis
was performed using one-way analysis of variance with the
Tukey’s multiple comparison test and two-tailed Student’s t
test (Prism 5.0, GraphPad Software). Statistical significance of
survival curves was assessed using the log-rank test. p values of
less than 0.05 were considered statistically significant.Western
blots were quantified using ImageJ software and analyzed for
relative density of bands.
Results
Wild-type Mice Demonstrate Rapid and Sustained Up-regu-
lation of FAP Expression in Two Murine Models of Pulmonary
Fibrosis—We verified that FAP is induced in two separate pul-
monary fibrosis models. Rapid and sustained induction of Fap
gene transcription occurred within 24 h of i.t. bleomycin
administration in C57BL/6 wild-type mice by RT-PCR (Fig.
1A). FapmRNA levels remained high even 14 days after injury
(Fig. 1A). Similarly, Fap gene expression was up-regulated by
24 h after thoracic irradiation (XRT) and remained elevated 4
months later, the latest time point analyzed (Fig. 1B). Fap gene
expression was undetectable in the lungs of FAPLacZ/LacZ mice
at all time points. Up-regulation of FAP expression in wild-type
mice after bleomycin was confirmed by IP/IB of whole lung
FIGURE 1. Rapid and sustained increase in FAP expression following bleomycin and XRT-induced lung injury. Kinetics of FAP mRNA induction in the
lungs of male C57BL/6mice after a single dose of i.t. bleomycin (1.75 IU/kg) (A) and in the lungs of female C57BL/6mice after a single dose of 13.5 Gy thoracic
irradiation (B). FAPmRNAexpression isnormalized to-actin. Inbothmodels, FAPgeneexpressionwasundetectable in the lungsof FAPLacZ/LacZmiceat all time
points. C, representative FAP IP/IB confirming induction of FAP at the protein level in wild-type C57BL/6 mouse lungs 7 days after i.t. bleomycin (top).
Densitometryof theFAP IP/IBbandsby Image J (bottom),n4pergroup.D, immunohistochemistry staining for FAPonparaffin-embedded lung sections from
mice 14 days after i.t. bleomycin versus saline.40, scale bar, 100 m.
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homogenates (Fig. 1C) and also by immunohistochemistry (Fig.
1D). Tissue staining (Fig. 1D) demonstrates FAP expression
predominantly on stromal cells rather than on the inflamma-
tory infiltrate or alveolar epithelial cells.
FAP-deficient Mice Show Decreased Survival Compared with
Wild-type Controls in Two Murine Models of Pulmonary
Fibrosis—FAP-deficient FAPLacZ/LacZ mice and age/sex-
matched wild-type controls received 1.0 IU/kg i.t. bleomycin
versus saline control or a single dose of 13.5 Gy thoracic irradi-
ation versus no treatment and were followed for survival. In the
bleomycinmodel, there wasminimal mortality in the wild-type
at the 1.0 IU/kg dose but 50%mortality in the FAPLacZ/LacZmice
(Fig. 2A). FAPLacZ/LacZ mice had roughly 50% mortality at 16
weeks after thoracic XRT comparedwith 25% inwild-type con-
trols (Fig. 2B).
FAP-deficient Mice Demonstrate Increased Lung Collagen
Content and Pulmonary Fibrosis Compared with Wild-type
Controls in Two Murine Models of Pulmonary Fibrosis—To
evaluate whether the increasedmortality in FAP-deficientmice
was caused by increased lung fibrosis, we assessed the lung col-
lagen content in both pulmonary fibrosis models by two inde-
pendentmethods as follows: 1) trichrome stain (Fig. 3,A andB),
and 2) a quantitative hydroxyproline assay (Fig. 3, C and D).
Trichrome staining suggested greater lung collagen content
following injury in FAP-null FAPLacZ/LacZ mice compared with
wild-type mice in both models. Quantification of lung collagen
content by hydroxyproline assay confirmed this. Interestingly,
untreated FAPLacZ/LacZ mice demonstrated a small but statis-
tically significant increase in lung hydroxyproline content at
the 16-week time point compared with untreated wild-type
controls (Fig. 3D). Similar to humans, mice develop a mild
degree of interstitial thickening and lung scarring with nor-
mal aging. Although not apparent in early adulthood (see
saline-treated animals, 10–14 weeks old, Fig. 3C), FAP-defi-
cient mice experience a slight acceleration in the gradual
increase in lung collagen content and fibrosis associated
with aging, a finding demonstrable at 24–28 weeks of age
(see Fig. 3D, untreated).
There Is No Apparent Difference in the Myofibroblast Popu-
lation in FAP-deficient and Wild-type Mice to Account for the
Difference in Phenotype—In recent years, the -SMA myofi-
broblast has commanded the attention of researchers in the
fibrosis field.With its enhanced contractile properties and exu-
berant matrix production, the myofibroblast has been high-
lighted as a key player in fibrogenesis (40–42). We therefore
investigated whether increased myofibroblast numbers in the
FAP-null mice compared with wild-type could be responsible
for the observed phenotype. Whole lung -SMA mRNA levels
were determined by RT-PCR in both fibrosis models (Fig. 4, A
and B), 7 days post-i.t. administration of bleomycin versus
saline and 16 weeks post-13.5Gy thoracic XRT versus no treat-
ment. Although -SMA expression was induced by bleomycin
exposure, there were no significant differences between FAP-
null and wild-type control mice within treatment groups (Fig.
4A). In theXRTmodel, there appeared to beminimal induction
ofmyofibroblasts (Fig. 4B); in fact, lung-SMA transcript levels
in treated mice trended lower than those in controls. Lung
-SMA immunofluorescence staining (Fig. 4,C andD) was per-
formed to confirm these mRNA findings. This was performed
at 14 days post-i.t. administration of bleomycin versus saline
and 16 weeks post-13.5 Gy thoracic radiation versus no treat-
ment. Objective quantification of percent -SMA staining per
total injured lung area revealed no differences between FAP-
deficient FAPLacZ/LacZ mice and wild-type mice after either i.t.
bleomycin or thoracic irradiation exposure (Fig. 4, E and F).
The FAP-null phenotype therefore did not appear to be
driven by differential induction of the -SMA myofibro-
blast population.
Increased Lung Fibrosis and Mortality in the FAP-null Mice
Cannot Be Attributed to Differences inMMP Activity or Known
Profibrotic Factors or Increased Collagen Synthesis—Gene
expression levels of multiple MMPs, Timp1, Pai-1, and Ctgf
(known players in fibrosis and collagen catabolism and turn-
over) were also assessed (Fig. 5). We found no significant dif-
ferences between bleomycin-treated FAP-null and wild-type
mice, although in the XRT model, there was a significant
decrease in Timp1 and Pai-1 transcript levels in the irradiated
FAP-null mice compared with wild type. Gelatin and collagen
zymography performed on whole lung lysates 10 days after
bleomycin administration revealed no discernable differences
in overallMMP enzymatic activity (Fig. 6).We assessed TIMP1
protein levels in the bleomycin model to see if differential
TIMP1 expression could be modulating MMP activity.
Although bleomycin induced TIMP1 expression, there was no
FIGURE 2.Decreased survival of FAP-deficient mice following bleomycin
and XRT-induced lung injury. A, decreased survival in male FAP-null
FAPLacZ/LacZmice versuswild-type controls after a single dose of i.t. bleomycin
(bleo) (1.0 IU/kg), * indicates p 	 0.01. Mice were followed for 24 days after
treatment. There were also statistically significant differences in survival
between saline versus bleomycin-treatedmice in each genotype, p	 0.01. B,
decreased survival in female FAP-null FAPLacZ/LacZ mice versuswild-type con-
trols after a single dose of 13.5 Gy thoracic irradiation, * indicates p 	 0.05.
Mice were followed for 16 weeks after treatment. There were also significant
differences in survival between untreated versus thoracic-irradiated mice in
each genotype, p 	 0.01. The number of animals per group is indicated in
parentheses.
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significant difference in TIMP1 levels in bleomycin-treated
FAP-null FAPLacZ/LacZ versus bleomycin-treated wild-type
mouse lungs (Fig. 7).
FAP-deficient PrimaryMouse Lung Fibroblasts DisplayMore
Robust Induction of the Myofibroblast Phenotype by TGF-
Compared with Wild Type—It is well accepted that TGF-
plays a pivotal role in the development of fibrosis. Produced by
multiple cell types, includingT cells,macrophages, neutrophils,
and fibroblasts, it is perhaps the most well known and potent
pro-fibrotic cytokine, functioning in some ways like a master
switch (43). We looked for evidence of enhanced TGF- acti-
vation in FAP-null FAPLacZ/LacZ mice by evaluating phospho-
Smad2 levels in whole lung homogenates in the bleomycin
model. Although there was a significant increase in phospho-
Smad2 levels between saline- and bleomycin-treated animals,
there was no significant difference in phospho-Smad2 levels
between the two genotypes within either treatment group (Fig.
8A). We also assessed TGF- production in FAP-deficient
FAPLacZ/LacZ versus wild-type primary mouse lung fibroblasts
in response to wounding using a mink luciferase epithelial cell
reporter assay and foundnodifferences between cell types (data
not shown).
Although therewas little evidence that alteredTGF- signal-
ing was responsible for the observed FAP-null phenotype at the
tissue level (Fig. 8A), this likely was due to the fact that the
multiple cell types present drowned out any fibroblast-specific
signal. We therefore proceeded to examine more cell type-spe-
cific responses and explored the effect of TGF- exposure on
primary mouse lung fibroblasts isolated from the lungs of
FAPLacZ/LacZ versuswild-type mice. This revealed a heightened
increase in phospho-Smad2 levels at 90 min (Fig. 8B) and
induction of -SMA at 48 h (Fig. 8C) and 72 h (data not shown)
in FAP-deficient primary mouse lung fibroblasts versus wild
type in response to TGF- stimulation. In addition, soluble
fragments of type I collagen in cell culture media were
increased in FAP-deficient primarymouse lung fibroblasts after
72 h of TGF- exposure compared with wild type (Fig. 8D).
Thismost likely reflects both increased type I collagen synthesis
in the presence of TGF- and decreased breakdown of inter-
mediate-sized collagen fragments in the absence of FAP. To
support this hypothesis, FAP-deficient primary mouse lung
fibroblasts display increased -SMA levels and increased
amounts of soluble type I collagen in cell culture media at base-
line, prior to TGF- stimulation (see CON in Fig. 8, C and D).
We assessedTGF receptor 1 and 2 levels as well as levels of the
inhibitory Smad6 and -7, butwe foundnodifferences that could
account for the observed differences in TGF- responses
between the two fibroblast cell types (data not shown).We then
explored whether FAP could cleave and thereby activate or
inactivate TGF- (Fig. 8E). FAP did not cleave either active or
inactive TGF- to any significant degree. Examination of the
protein sequence of TGF- did reveal a possible PPGP cleavage
site in the LAP. Incubation of recombinant murine FAP with
recombinant human LAP did generate two faint new smaller
FIGURE 3. Excess accumulation of collagen in FAP-deficient mice following bleomycin and XRT-induced lung injury. A, representative trichrome
staining of lungs from FAP-deficient FAPLacZ/LacZ versus wild-type mice 14 days after i.t. bleomycin (Bleo) (1.75 IU/kg) versus saline, 20, scale bar, 200
m. B, representative trichrome staining of lungs from FAP-deficient FAPLacZ/LacZ versuswild-typemice 16 weeks after 13.5 Gy thoracic irradiation versus
no treatment, 20, scale bar, 200 m. C, quantification of total right lung collagen content by hydroxyproline assay 14 days after i.t. bleomycin (1.0
IU/kg) administration, n 5–10mice per group. There was a significant increase in lung hydroxyproline content between saline- and bleomycin-treated
mice for each genotype, p 	 0.01. D, quantification of right lung collagen content by hydroxyproline assay 16 weeks after 13.5 Gy thoracic irradiation
versus no treatment, n  4–8 mice per group. There was also a significant increase in lung hydroxyproline content between untreated and thoracic-
irradiated mice in each genotype, p 	 0.01.
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protein bands, indicating a modest degree of LAP cleavage by
FAP (indicated by arrows in Fig. 8E). These bands disappeared
when FAP was preincubated with the FAP inhibitor, showing
specificity of the result. The significance of this finding, how-
ever, is unclear.
We investigated whether FAP-null mice might produce
more collagen in response to lung injury than wild-type mice.
mRNA levels of several major collagen isoforms found in the
lung (i.e. collagen 11, 12, and 31) were significantly up-
regulated following injury in both pulmonary fibrosis models
(Fig. 9A). However, no significant differences in lung tran-
script levels of these collagen isoforms were found between
the two genotypes after bleomycin treatment. In the XRT
model, irradiated FAP-null mice actually had lower mRNA
levels of these collagen isoforms compared with their irradi-
ated wild-type counterparts, perhaps due to a negative feed-
back mechanism.
FAP Participates in Type 1 Collagen Catabolism after Prior
MMP-mediated Cleavage of Intact Collagen to Its 3⁄4- and 1⁄4-
Length Fragments—The data above revealed increased collagen
accumulation in FAP-null mice compared with controls in the
absence of evidence for increased collagen synthesis or altera-
tions in other proteases/factors typically associated with colla-
gen turnover. We therefore postulated that FAP itself plays an
essential role in collagen proteolysis and ECM remodeling so
that absence of FAP activity leads to impaired collagen break-
FIGURE 4. FAP does not regulate-SMA expression following lung injury. A, -SMAmRNA levels were higher 7 days after i.t bleomycin (Bleo) in both
wild-type and FAPLacZ/LacZ mice compared with controls by RT-PCR, but there was no significant difference in -SMA transcript levels between the two
genotypes when comparing within treatment groups. -SMA mRNA expression is normalized to -actin. n  3/group. B, trend toward a decrease in
-SMA mRNA expression in mice of both genotypes by RT-PCR 16 weeks after 13.5 Gy thoracic irradiation compared with no treatment, but these
differences were not statistically significant. -SMA mRNA expression is normalized to -actin. n  3–5/group. C, representative -SMA immunofluo-
rescence staining of lungs from FAPLacZ/LacZ and wild-type mice 14 days after i.t bleomycin. Sections from saline-treated animals are not shown as they
had virtually no fibroblast-associated -SMA staining.20, scale bar, 200 m. n 4/group. D, representative -SMA immunofluorescence staining of
lungs from FAPLacZ/LacZ and wild-type mice 16 weeks after 13.5 Gy thoracic irradiation. Sections from untreated animals are not shown as they had
virtually no fibroblast-associated -SMA staining. 20, scale bar, 200 m. n  4/group. E, quantification of -SMA staining in the bleomycin-treated
mice by ImageJ. All five lung lobes from eachmouse were examined with four40 images taken per lobe and analyzed in blinded fashion by an ImageJ
macro designed to quantify the area positive for -SMA staining within areas of lung injury. Total area positive for -SMA immunofluorescence was
divided by total injured area for each mouse. n 4/group. F, quantification of -SMA staining in the irradiated mice by ImageJ in the same manner as
described in E. n  3–4/group.
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down and clearance after lung injury. We analyzed the
sequence of type I collagen for defined consensus FAP target
sequences (endopeptidase, DGESGP and DRGETGP; DPP,
PPGP) and found innumerable potential DPP cleavage sites for
FAP along the length of the 11 chain of the type I collagen
fibril (data not shown). Analogous siteswere alsomapped to the
12 chain of type I collagen and the 31 chain of type III colla-
gen (data not shown).
In vitro studies sought to confirm a reported lack of FAP
collagenase activity (Fig. 9B) (22). Incubation of type 1 collagen
gels with purified recombinantmurine FAPECDalone (Fig. 9B,
lane 2) failed to yield soluble collagen fragments. Collagen pro-
cessing by FAP did require prior cleavage of collagen by MMP.
Although unable to release fragments from intact collagen gels,
FAP readily degradedMMP-generated 3⁄4 and 1⁄4 length collagen
fragments to smaller fragments in a dose-dependent manner
(Fig. 9B, lanes 4–7). The specificity of this finding was con-
firmed as pre-incubation with PT630, a FAP and DPPIV
inhibitor (24), prevented subsequent digestion of the MMP-
generated 3⁄4 and 1⁄4 length collagen fragments by FAP (Fig.
9B, lane 8).
These data indicate a direct role for FAP, in an ordered
sequence with collagenase MMPs such as MMP1, in collag-
enolysis. Similar results were obtained with type III collagen
(data not shown). MMP and MMP-FAP collagen digests were
also resolved by HPLC and the fractions analyzed by gel elec-
trophoresis (data not shown). This analysis demonstrated some
degree of preservation of the quaternary structure of collagen,
particularly in the MMP-only digests while also, to a lesser
extent, following sequential digestion with MMP and FAP-
ECD. HPLC also confirmed generation of an array of small col-
lagen fragments from cleavage of 3⁄4 and 1⁄4 length fragments by
FAP-ECD.
Intermediate-sized Collagen Fragments, Detectable in the
Lungs of Wild-type Mice after Bleomycin, Are Present in the
Lungs of FAP-deficient Mice at Baseline, Indicating a Defect in
Collagen Turnover and Clearance—We sought evidence for
FAP-dependent ordered proteolysis of collagen fragments in
vivo.We postulated that intermediate-sized collagen fragments
(i.e. 3⁄4 and 1⁄4 length fragments, for example) may persist longer
in the extracellular matrix of FAP-null mice due to impaired
collagen processing and turnover. To test this hypothesis, total
lung ECM was isolated frommice 10 days after treatment with
either saline or bleomycin via an established SDS-based decel-
lularization protocol (37). Resolved lung ECM proteins were
probed with a type I collagen antibody that recognizes various-
sized collagen fragments as well as intact collagen. This analysis
revealed increased intermediate-sized collagen fragments
FIGURE 5. Levels of MMPs and several other known pro-fibrotic factors are similar in the lungs of FAPLacZ/LacZ andwild-typemice after i.t. bleomycin
or thoracic irradiation. A, lung mRNA levels of multiple MMPs and several known profibrotic factors were measured by RT-PCR in mice 7 days after i.t.
bleomycin (Bleo) (1.75 IU/kg) versus saline (A) and 16 weeks after thoracic irradiation (13.5 Gy) versus untreated (B). n 3 mice per group, mRNA levels were
normalized to -actin. # indicates a significant difference betweenwild-type control andwild-type treatedmice, p	 0.05. ## indicates a significant difference
betweencontrol and treatedmice forbothgenotypes,p	0.05. * indicates a significantdifferencebetweenXRT-treatedFAPLacZ/LacZ andXRT-treatedwild-type
mice, p	 0.05.
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(
70–120 and 
30–45 kDa) in the ECM isolated from FAP-
null mice at baseline (Fig. 10A, lane 2). In contrast to lung ECM
extracts from FAP-null mice, lung ECM extracts from
untreated wild-type mice, which had similar levels of intact
collagen, did not contain detectable levels of intermediate-sized
collagen fragments at baseline (Fig. 10A, 1st lane). After bleo-
mycin, however, intermediate-sized collagen fragments were
detectable in the wild-type lung ECM extracts (Fig. 10A, 3rd
lane). Interestingly, further increase in intermediate-sized col-
lagen fragments was not evident in the FAP-null mice after
bleomycin treatment (Fig. 10A, 4th lane). Immunoblots for type
I collagen in whole lung homogenates (Fig. 10B) from mice in
our bleomycin experiments provided data very similar to our
decellularized lung ECM extracts in Fig. 10A. Although intact
collagen would not be present in these homogenates due to
solubility issues, smaller, partially degraded collagen fragments
should be soluble in standard lysis buffers and therefore recov-
erable. These blots do show an increase in type 1 collagen frag-
ments (see 
60-kDa fragment) in the FAP-null mice at base-
line, with a further increase in the 
60-kDa fragment with
bleomycin treatment in both groups (Fig. 10B). These results
echo what we saw in the ECM preparations made from decel-
lularized lungs solubilized in protein extraction reagent 4 from
Sigma (Fig 10A). We again, however, saw no significant differ-
ence in type I collagen fragment burden between the two bleo-
mycin-treated groups. Bleomycin, in addition to causing a
fibrotic response, also induces a strong inflammatory reaction.
We suspect that in the bleomycin-treated animals, the influx of
inflammatory cells, including phagocytes such asmacrophages,
may partially curb the accumulation of collagen fragments to
some extent and make it difficult to appreciate subtle differ-
ences in the quantities of less abundant intermediate-sized col-
lagen fragments.
FAP Fibroblasts DemonstrateMore Efficient Collagen Inter-
nalization than FAP-null Fibroblasts—Cleavage of intact colla-
gen to smaller fragments facilitates its uptake intomacrophages
and fibroblasts and thereby accelerates matrix turnover. We
postulated that collagen cleavage by cells expressing FAP on
their surface contributes to efficient collagen internalization.
Type I collagen was labeled with DyLight 650 to eliminate any
issues with background autofluorescence from the primary
lung fibroblasts or from collagen itself. We established that
after labeling, the collagen was still amenable to cleavage by
proteases (Fig 11A). FAPwild-type primarymouse lung fibro-
blasts and FAP-null FAPLacZ/LacZ primary mouse lung fibro-
blasts were seeded on DL650 collagen gels in the presence of
FIGURE 6. MMPs are similarly induced in FAPLacZ/LacZ versus wild-type mice by intratracheal bleomycin. A, representative gelatin zymogram showing
MMP gelatinase activity in whole lung homogenates from FAPLacZ/LacZ versuswild-typemice 10 days after i.t. bleomycin (Bleo) (1.75 IU/kg) versus saline. n 5
mice per group. 20 g of protein was loaded per lane. B, representative collagen zymogram showing MMP collagenase activity in whole lung homogenates
from FAPLacZ/LacZ versus wild-type mice 10 days after i.t. bleomycin versus saline. n 3 mice per group. 50 g of protein was loaded per lane. C and D show
ImageJ densitometry quantification of bands seen in A and B, respectively.
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lysosomal inhibitor E-64d and later recovered from the gels
by collagenase/trypsin digest and seeded on fibronectin-
coated glass coverslips for confocal microscopy examination.
FAP wild-type fibroblasts demonstrated greater uptake of
DL650-labeled collagen by quantitative analysis (Fig. 11B).
Treatment with a selective pharmacologic FAP inhibitor,
N-(quinoline-4-carbonyl)-Gly-Pro(F,F)-nitrile, significantly
decreased DL650-labeled collagen uptake by FAP wild-
type primary mouse lung fibroblasts (Fig. 11D). We evalu-
ated for differences in expression of Endo180 (also known as
uPARAP), the major receptor through which both intact and
proteolytically cleaved fibrillary collagen is internalized and
cleared by fibroblasts (44–47). Levels of Endo180 were sim-
ilar between FAP wild-type and FAP-null FAPLacZ/LacZ pri-
mary lung fibroblasts (Fig 11C). Processing and cleavage of
intermediate-sized (i.e. 3⁄4 and 1⁄4) collagen fragments to
smaller fragments by FAP thus directly facilitates collagen
internalization by macrophages and fibroblasts, promoting
matrix remodeling and restoration of lung homeostasis.
Reconstitution of FAP Expression by Adenoviral Gene Deliv-
ery Rescues FAP-deficient Mice and Decreases the Degree of
Lung Fibrosis after Bleomycin Back to Levels of Wild-type
Controls—Up to this point, we had shown that FAP deficiency
predisposes tomore severe lung fibrosis after injury in our bleo-
mycin and thoracic irradiation models. To more directly show
that FAP expression is protective in the murine lung, we per-
formed reconstitution experiments. First, primary mouse lung
fibroblasts derived from FAPLacZ/LacZ mice and wild-type con-
trols (data not shown) were transduced with replication-defi-
cient adenovirus expressing recombinant human FAP (adeno-
hFAP) and empty vector (adeno-Y5). We confirmed robust
hFAP expression 72 h later at a multiplicity of infection of 10
with further augmentation at a multiplicity of infection of 20
(Fig. 12A). No significant cellular toxicity was noted. We then
established the effective dose of adeno-hFAP in vivo. 108 pfu of
adeno-hFAP given via intratracheal injection was sufficient to
cause robust hFAP expression at themRNA (Fig. 12B) and pro-
tein (Fig. 12C) level by day 3 after adenovirus administration,
which was relatively sustained, although there was some evi-
dence that protein levels began to drop off by day 10 and
definitely by day 15 (Fig. 12C, better appreciated in the
FAPLacZ/LacZ IPIB,upper blot). This dose of adenoviruswaswell
tolerated by the mice. A reconstitution experiment was then
performed. FAPLacZ/LacZ mice and age/sex-matched wild-type
controls were given 108 pfu adeno-hFAP versus adeno-Y5 via
intratracheal injection followed by intratracheal bleomycin
administration 72 h later. There was a significant reduction,
back to levels similar to wild-type, in lung hydroxyproline con-
tent in the bleomycin-treated FAPLacZ/LacZ mice receiving i.t.
adeno-hFAP compared with bleomycin-treated FAPLacZ/LacZ
mice receiving adeno-Y5 (Fig. 12D), amounting to rescue of the
FAP-deficient phenotype with FAP overexpression. Bleomy-
cin-treated wild-type mice receiving adeno-hFAP had equiva-
lent lung hydroxyproline content to bleomycin-treated wild-
typemice receiving adeno-Y5, so FAP overexpression beyond a
certain point did not seem to confer additional benefit. Some
limitations of the adenoviral overexpression approach may
have affected our findings, namely the induction of ectopic FAP
expression in lung epithelial cells as well as possibly other cell
types besides lung fibroblasts, and also the unavoidable acute
bystander inflammation induced by the adenoviral infection
itself.
Discussion
In our ever-aging population, morbidity and mortality from
pulmonary fibrosis continues to rise, with overall mortality
from pulmonary fibrosis now outstripping that associated with
several malignancies such as bladder cancer, acute myeloge-
nous leukemia, and multiple myeloma (48). Without question,
there is a compelling need for better insight into the events that
govern the conversion of what begins as a normal healing pro-
cess after lung injury into an uncontrolled fibroproliferative
response resulting in irreversible scarring, tissue distortion, and
progressive decline in lung function.
The scientific literature supports a role for aberrant regula-
tion of cell surface and matrix-associated proteases in the
pathogenesis of pulmonary fibrosis (49–52).MMPs (49, 50, 53),
neutrophil elastase (54, 55), and proteinases of the coagulation
cascade (56–60) have all been implicated in the disease.
Although the balance of the literature to date indicates a pro-
fibrotic action of these particular proteases, we have found that
FAP, a serine protease in the DPP family, exerts a protective
anti-fibrotic effect in the setting of lung injury. This may at first
seem counterintuitive as proteins up-regulated in disease tend
to serve a pathologic role. However, the scientific literature cat-
alogues a growing number of proteins up-regulated in disease
that work to counter the disease process, reestablish homeosta-
sis, and return the body to its original state of health (61–63),
and we have found that FAP behaves in such a fashion in pul-
monary fibrosis.
FIGURE 7. TIMP1 is similarly induced at the protein level in FAPLacZ/LacZ
versus wild-type mice after intratracheal bleomycin. A, representative
Western blot of whole lung homogenates from mice 10 days after intratra-
cheal bleomycin (Bleo) (1.75 IU/kg) versus saline. B, ImageJ densitometry
quantification of TIMP1 band intensity in saline versus bleomycin-treated
mouse lunghomogenates onWestern blot, normalized to-actin.n 3mice
per saline-treated group; n 5 mice per bleomycin-treated group.
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This study is the first to demonstrate that the absence of FAP
worsens the development of pulmonary fibrosis after lung
injury, establishing a protective role for FAP in the lung. In
designing the murine studies that ultimately led to this conclu-
sion, we elected to conduct both thoracic irradiation and i.t.
bleomycin experiments because the two fibrosis models com-
plement each other. Bleomycin gives us insight into events ear-
lier in the development of pulmonary fibrosis, when dysregu-
lated lung remodeling andmatrix depositionmay be reversible,
whereas thoracic irradiation allows us to study chronic and
more advanced stages of disease.We did not necessarily expect
the two models to yield the same outcomes. In the end, how-
ever, FAP-deficient mice experienced decreased survival and
increased fibrosis compared with wild type in both models,
which validates and strengthens our findings.
Very simplistically, fibrosis can be understood as an imbal-
ance between collagen synthesis and collagen catabolism and
clearance. Although much ongoing effort has been appropri-
ately directed at studying the activated fibroblast/myofibro-
blast as the prime mediator(s) of collagen overproduction in
fibrosis, less examination has been given to the competing
events of matrix remodeling, collagen turnover, and scar
resorption. Collagen turnover has been described to occur
through two processes, somewhat interrelated. The first is
the extracellular/pericellular proteolytic cleavage of colla-
gen, classically by MMPs with collagenase (i.e. MMP1, -8,
-13, and -14) followed by those with gelatinase (i.e. MMP2
and -9) activity, although other proteases likely participate as
well, including FAP as indicated by our current study (64–
67). The second event involves endocytosis of collagen
FIGURE 8. Although overall activation of the TGF- pathway appears similar in the lungs of FAPLacZ/LacZ versuswild-type mice after i.t. bleomy-
cin administration, FAP-deficient fibroblasts develop amore robust myofibroblast phenotype in response to TGF- compared with wild-type.
A, representative immunoblot of phospho-Smad2 normalized to total Smad 2/3 in whole lung homogenates frommice 14 days after i.t. bleomycin (Bleo)
(1.75 IU/kg) versus saline. Densitometry was performed by ImageJ. n 3 mice per group. ** indicates p	 0.01. B and C, primary mouse lung fibroblasts
derived from FAPLac/LacZ versus wild-type mice were cultured on collagen-coated plates and treated with TGF- (10 ng/ml) versus vehicle control. B,
representative immunoblot for phospho-Smad2 versus total Smad2/3 after 90 min TGF- versus vehicle control (CON) exposure. C, representative
immunoblot for -SMA normalized to -actin after 48 h of TGF- stimulation versus vehicle control. D, primary mouse lung fibroblasts derived from
FAPLac/LacZ versus wild-type mice were cultured on uncoated plates and treated with TGF- (10 ng/ml) versus vehicle control. Cell culture media were
assessed 72 h later for the presence of type 1 collagen fragments. A representative immunoblot is shown. B–D, densitometry for these fibroblast
experiments was performed by ImageJ. n 3 independent samples per group. * indicates p	 0.05; ** indicates p	 0.01. All fibroblast experiments were
repeated in triplicate. E, FAP does not cleave active or latent TGF- but does cleave LAP to some extent. 1 g of 1) active recombinant human TGF-
(TGF), 2) latent TGF- (LTGF), and 3) recombinant human LAP were incubated at 37 °C for 16 h either 1) alone, 2) with 2.5 g of recombinant murine
FAP (FAP), or 3) with 2.5 g of recombinant murine FAP preincubated with a selective FAP inhibitor, N-(quinolone-4-carbonyl)-Gly-Pro(F,F)-nitrile
(FAP/I), for 15 min. Samples were then resolved on a 4–12% Bis-Tris gel and stained with colloidal silver. Black arrows highlight new bands indicating a
small degree of cleavage of LAP by FAP.
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through interaction with cell surface receptors, in particular
21 integrin and uPARAP/Endo180, with subsequent deg-
radation of the internalized collagen within the lysosomal
compartment (45, 47, 68–70). Although intact collagen may
be endocytosed, fragmentation of collagen greatly speeds its
rate of internalization and clearance (44, 71). Collagen inter-
nalization through uPARAP/Endo180 has been implicated
in both tumorigenesis and the development of fibrosis in the
liver and lung in vivo (46, 47, 72).
Our study establishes an important role for FAP in collagen
clearance and matrix turnover. Although FAP is unable to
cleave intact type 1 collagen, our in vitro assay clearly demon-
strates the ability of FAP to process 3⁄4 and 1⁄4 length collagen
fragments generated by prior MMP exposure into smaller deg-
radation products, facilitating their clearance. We were able to
detect intermediate-sized collagen fragments in total lungECM
preparations as well as in whole lung homogenates from FAP-
null mice at baseline, although these mid-sized collagen frag-
ments were absent in lung ECM extracts and less abundant in
whole lung homogenates from saline-treated wild-type mice.
These data suggest that animals lacking FAP activity have a
defect in collagen catabolism even under homeostatic condi-
tions, hence collagen fragments that are normally not pres-
ent in detectable quantities or at least present at very low
levels are found accumulating in the FAP-null mice. Both
wild-type and FAP-null mice demonstrated the presence of
FIGURE 9. FAPmediates degradation of MMP1-derived collagen cleavage products in vitro. A, relative lung Col11, Col12, and Col31 mRNA levels in
FAPLacZ/LacZ andwild-typemice 7 days after i.t. bleomycin (Bleo) (treated) versus saline (control) or 16weeks after 13.5 Gy thoracic irradiation (treated) versusno
treatment (control), normalized to-actin. #, p	 0.05 comparing control versus treated groups for the designated genotype. *, p	 0.05 comparing genotypes
within thedesignated treatmentgroup.B, type I collagendigestswith recombinantMMP1 recombinantmurineFAPextracellular domain (rFAP-ECD). Rat tail
type I collagenwas untreated (input, lane 1) or solidified and then digestedwith rFAP-ECD alone (lane 2) or with 0.75g of recombinant humanMMP-1 (lanes
3–8). In lanes 3–8, GM6001was added after 8 h to halt furtherMMP activity, and then further digestionwas performedwith the indicatedmicrogram amounts
of purified rFAP-ECD (lanes 4–8) for an additional 8 h in the absence (lanes 4–7) or presence of the FAP inhibitor PT630 (lane 8). The soluble fraction was then
resolved on a 4–12% Bis-Tris gel and stained with Coomassie Blue.
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intermediate-sized collagen fragments in lung ECM extracts
and whole lung homogenates after i.t. bleomycin, likely
related to increased collagen turnover in the setting of lung
injury. In wild-type mice, we reason that these fragments
appear after bleomycin treatment because the accelerated
rate of collagen turnover in the setting of inflammation, scar-
ring, and increased collagen production and fibrosis exceeds
the enzymatic limits of FAP and other gelatinases present in
tissues. This allows these intermediate-sized collagen frag-
ments to be transiently seen, whereas under normal circum-
stances they would not be detectable.
Manymight question whether FAP plays a significant role in
collagen degradation in vivo, because multiple MMPs possess-
ing gelatinase activity similarly cleave 3⁄4 and 1⁄4 length collagen
fragments into smaller fragments indicating some redundancy
of function. However, the detection of intermediate-sized
collagen fragments in lung ECM isolated from FAP-null
mice but not from B6 wild-type mice indicates that FAP
indeed plays a significant role in collagen turnover in vivo,
because its absence alters collagen composition. A recent
study from our laboratory also supports a role for FAP in
collagen turnover as CD26 tumors in FAP-null mice demon-
strate dramatically increased amounts of collagen stroma as
do tumors in wild-type mice in which the enzymatic activity
of FAP has been pharmacologically inhibited (24). Further-
more, our finding that FAP fibroblasts more effectively
internalize collagen compared with FAP-null cells confirms
an important functional role for the protein in fibrogenesis.
Our data are supported by a recent independent study where
a genome-wide RNA interference screen in Drosophila S2
cells identified FAP as one of 22 candidate genes associated
with increased collagen uptake (73). Finally, our data show-
ing that FAP expression appears to modulate TGF--medi-
ated myofibroblast differentiation suggests that FAP may be
very important in regulating the fibrogenic response after
lung injury. On the basis of these results, we propose that
FAP plays a larger role in ECM remodeling in vivo than has
been previously appreciated, commensurate and in concert
with the more widely studied MMPs.
Our study has several important implications. It points to a
previously unrecognized, essential role for FAP in matrix
remodeling and collagen clearance in the lung and identifies
FAP as a novel endogenous regulator of fibrosis. Although a
better understanding of myofibroblast biology might allow one
to turn off collagen production by this cell type, the ability to
accelerate collagen degradation could mean not only halting
further scar formation but achieving resorption of collagen and
reversal of established fibrosis. This has major implications for
the field of pulmonarymedicine, in particular interstitial lung dis-
ease. Having shown FAP to play a protective, homeostatic role in
the lung, promoting resorption of scar by direct participation in
collagen catabolism and clearance and dampening myofibroblast
induction in response to TGF-, we now may consider ways to
increase FAP expression, enhance enzymatic activity, and/or tar-
get downstream effectors in the future to try to minimize the
development of lung fibrosis in certain scenarios.
Our study has important ramifications for cancer biology.
FAP is already a protein of great interest in the cancer field, with
FIGURE 10. FAP deficiency leads to accumulation of partially processed intermediate-sized collagen fragments in vivo. A, representative immu-
noblot for type 1 collagen in decellularized lung ECM extracts from wild-type and FAPLacZ/LacZ mice 10 days after i.t. bleomycin versus saline. Equal
amounts of protein were resolved on 3–8% Tris acetate (not shown here) and 4–12% Bis-Tris gels and then probed for type 1 collagen. Lung ECM sample
order is as follows: 1st lane, WT saline-treated; 2nd lane, FAP-null saline-treated; 3rd lane, WT bleo-treated; 4th lane, FAP-null bleomycin (Bleo)-treated.
This experiment was repeated in triplicate. B, representative immunoblot of whole lung homogenates frommice 14 days after i.t. bleomycin (1.0 IU/kg)
versus saline resolved on a 4–12% Bis-Tris gel and probed for type 1 collagen. Black arrow indicates 
60-kDa fragment quantified by densitometry
(ImageJ) below. n  3 independent samples per group. * indicates p 	 0.05.
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many groups working on potential means of safe pharmaco-
logic inhibition of FAP to target the tumor microenvironment
or stroma. In light of our findings, however, one must proceed
with somewhat heightened caution in such endeavors. Many
patients with primary lung cancers or other intrathoracic
malignancies undergo adjuvant radiation therapy for local
tumor control and/or chemotherapy. If future treatment regi-
mens include a pharmacologic inhibitor of FAP, we need to
ensure that patients will not be at increased risk of developing
radiation-induced or chemotherapy-related interstitial lung
disease. A better understanding of the role of FAP in human
fibrosing conditions is required.
The potential biological significance of the intermediate-
sized collagen fragments that accumulate in FAP-null animals
at baseline and in both genotypes after lung injury should also
be mentioned. Previous work by others has shown significant
biological activity of peptides generated fromproteolytic degrada-
tion of collagens, for example the chemotactic properties of the
matrikine, PGP, or the antifibrotic actions of endostatin, a product
of proteolytic degradation of collagen XVIII (61, 74, 75). Indeed,
we did identify increased neutrophilic inflammation in BAL fluid
from FAP-null mice compared with wild type in our bleomycin
model as well as amore prominent inflammatory infiltrate overall
in the BAL from FAP-null mice versus wild type after thoracic
FIGURE 11. FAP wild-type primary lung fibroblasts internalize type I collagen more efficiently than FAP-null fibroblasts. A, DL650-labeled collagen
(intact, unpolymerized, 1st lane) versus MMP-1-digested (2nd lane) versus MMP-1 followed by FAP ECD-digested (3rd lane) DL650-labeled collagen were
resolvedona4–12%Bis-Tris gel, and thegelwas imaged in theCy5channel byaTyphoon imager. Fluorescent labelingdidnot impedeproteolytic degradation
of the collagen. B,primarymouse lung fibroblasts derived fromFAPwild-type and FAP-null FAPLacZ/LacZmicewere seededonDL650-labeled collagengels for
9 h, in thepresence of E-64d, a lysosomal inhibitor, then recoveredby collagenase/trypsin digest, seededon fibronectin-coatedglass coverslips, and examined
by confocal microscopy. DL650 fluorescence/cell was quantified by Metamorph software. Red, internalized DL650-labeled collagen; blue, Hoechst dye; green,
F-actin. C, cell lysates from untreated primary mouse lung fibroblasts (P3) derived from FAP wild-type and FAP-null FAPLacZ/LacZ mice were probed for the
collagen receptor, Endo180; reference protein GAPDH. n 5 independent samples per group. D, pretreatment of primary wild-type mouse lung fibroblasts
with a selective FAP inhibitor, N-(quinoline-4-carbonyl)-Gly-Pro(F,F)-nitrile, significantly reduces collagen internalization by FAP fibroblasts. Primary mouse
lung fibroblasts derived from FAPwild-type mice were pretreated for an hour and then maintained in the selective FAP inhibitor, N-(quinoline-4-carbonyl)-
Gly-Pro(F,F)-nitrile, or vehicle control at 1 mM concentration for the duration of the experiment. After pretreatment, primary mouse lung fibroblasts were
seeded on DL650-labeled collagen gels for 9 h, in the presence of E-64d, a lysosomal inhibitor, then recovered by collagenase/trypsin digest, seeded on
fibronectin-coatedglass coverslips, and examinedby confocalmicroscopy. DL650 fluorescence/cellwas quantifiedbyNIS Elements software.Red, internalized
DL650-labeled collagen; blue, Hoechst dye; green, F-actin.
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irradiation (data not shown). So beyond the simple physical accu-
mulation of collagen and collagen fragments within the intersti-
tiumof the lung in the absence of FAP, onemust also consider the
possibility that thepresenceorabsenceofcertainproductsofECM
turnover and their biological effects may contribute to enhanced
fibrogenesis as well (see proposed schema, Fig. 12E). Finally, it is
possible, andperhapseven likely, thatFAPmaycleaveother essen-
tial proteins involved in the pathogenesis of pulmonary fibrosis
besides collagens and influence the development of the disease
through yet another mechanism.
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